Marker Therapeutics Inc. (NASDAQ: MRKR) Near the Top of Equities by Percentage Gain on 12/11Marker Therapeutics, Inc. (
NASDAQMRKR) is one of today’s top gainers. The company’s shares have moved 1.92% on the day to $2.65.
Marker Therapeutics Inc. (NASDAQ: MRKR) Near the Top of Equities by Percentage Gain on 7/24Marker Therapeutics, Inc. (
NASDAQMRKR) is one of today’s top gainers. The company’s shares are currently up 18.53% on the day to $7.83.
Marker Therapeutics Inc. (NASDAQ: MRKR) Leading the Way in Friday Trading Based on Percentage GainMarker Therapeutics, Inc. (
NASDAQMRKR) is one of today’s top gainers. The company’s shares are currently up 13.94% on the day to $2.37.
Marker Therapeutics (NASDAQ: MRKR) Announces Leadership Transition and Strategic Partnership with CellReady to Strengthen Financial Position Through 2025Houston-based Marker Therapeutics, Inc. (Nasdaq: MRKR) operates as a clinical-stage company focused on developing advanced T cell-based immunotherapies for hematological
Why Legend Biotech Stock Is Having Its Best Month YetWith the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer TreatmentPalm Beach, FL –May 20, 2021 – Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of years. Revenues will increase but so will money flow into R&D efforts to treat this condition. Pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period. The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc. Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (
NASDAQONCY) (TSX: ONC), Athenex, Inc.
NASDAQ: ATNXNASDAQATNX)
(NASDAQ: SEELNASDAQSEEL
, Trillium Therapeutics Inc. (NASDAQ: TRILNASDAQ
) (TSX: TRIL), Marker Therapeutics, Inc. (NASDAQ: MRKR
MRKR).
